NeuroEPO-Stroke. Phase I-II |
11/09/2014 |
CIMAB |
NeuroEPO-Ataxia-Adults-Phase III |
19/11/2020 |
CIM |
NeuroEPO – Type 2 Spinocerebellar Ataxia Phase I-II |
02/11/2014 |
CIMAB |
NeuroEPO in patients with Mild-Moderate Alzheimer's disease |
01/02/2017 |
CIM |
NeuroEPO in mild-moderate Alzheimer's disease amnesic variant |
22/09/2022 |
CIM |
NeuroEPO in mild-moderate Alzheimer's disease |
20/09/2022 |
CIM |
NASVAC Phase II Trial in patients with Chronic Hepatitis B Virus infection |
2012-10-12 |
CIGB |
Nasalferon in ARI |
29/07/2022 |
CIGB |
Nasal recombinant human interferon alfa-2b in ARI |
06/12/2022 |
CIGB |
MEÑIQUE Study |
03/09/2021 |
CIGB |
Melagenina Plus - Vitiligo – phase IV |
14/01/2019 |
CHP |
MAMBISA Study |
26/11/2020 |
CIGB |
Lithium Carbonate-COVID-19- mild and moderate -Exploratory / Phase II |
05/08/2021 |
ICBPGirón |
Kardioli® nutritional supplement versus placebo in patients with chronic heart failure. Phase II. |
03/03/2023 |
CATALYSIS |
Jusvinza in Severe Patients with Acquired Community Pneumonia |
14/10/2022 |
CIGB |
Jusvinza in rheumatoid arthritis |
20/04/2022 |
CIGB |
Itolizumab-Plasmapheresis in patients with COVID-19 |
30/06/2021 |
CIM |
Itolizumab Safety and Efficacy Study in Covid 19 |
26/03/2021 |
CIM |
Itolizumab for Relapsing Remitting Multiple Sclerosis |
22/05/2015 |
CIM |
Itolizumab for Moderate-to-Severe Psoriasis-phase 3 |
08/10/2015 |
CIM |